Burkhard Beyer1, Philipp Mandel2, Uwe Michl1, Raisa S Pompe1, Valia Veleva1, Thomas Steuber1, Hartwig Huland1, Markus Graefen1, Derya Tilki3,4. 1. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. 2. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 3. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. d.tilki@uke.de. 4. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. d.tilki@uke.de.
Abstract
PURPOSE: Oncological surgery in immunosuppressed patients with solid organ transplantation (Tx) is challenging. These patients are thought to have higher postoperative morbidity and an increased rate of tumour progression. The aim of the present study was to analyse oncological, functional and perioperative outcomes in Tx patients following radical prostatectomy (RP). MATERIALS AND METHODS: Between 1996 and 2014, 30 patients diagnosed with prostate cancer underwent RP at our institution following Tx (kidney: n = 20, heart: n = 5, liver: n = 5). Functional, oncological and perioperative follow-ups were analysed. Postoperative complications were assessed using the Clavien-Dindo classification. RESULTS: Median follow-up was 45 months. Median PSA was 5.3 ng/ml. Intraoperative blood loss was 600 ml at a median operating time of 180 min. Surgery in kidney Tx patients was technically feasible. Major complications occurred in 3 patients (ureteral injury, lymphocele and haematoma). Histological evaluation revealed n = 18 ≤pT2 tumours (60.0 %), n = 7 pT3a tumours (23.3 %) and n = 5 ≥pT3b tumours (16.7 %). Continence rate 12 months after surgery, defined as no or one safety pad use, was 73.3 %, while 93.3 % of the patients used ≤2 pads/24 h. After the median follow-up of 45 months, BCR-free survival was 69.0 %. In recurrent men, there was suspicion of metastasis in one patient. No cancer-specific death was observed. Five-year overall survival was 94.4 %. CONCLUSION: The complication rate in patients with solid organ transplantation after RP was low. While histopathological evaluation revealed disease characteristics comparable to non-transplant patients from current RP series, postoperative continence was worse. Immunosuppressive therapy does not seem to lead to an increased rate of tumour progression.
PURPOSE: Oncological surgery in immunosuppressed patients with solid organ transplantation (Tx) is challenging. These patients are thought to have higher postoperative morbidity and an increased rate of tumour progression. The aim of the present study was to analyse oncological, functional and perioperative outcomes in Tx patients following radical prostatectomy (RP). MATERIALS AND METHODS: Between 1996 and 2014, 30 patients diagnosed with prostate cancer underwent RP at our institution following Tx (kidney: n = 20, heart: n = 5, liver: n = 5). Functional, oncological and perioperative follow-ups were analysed. Postoperative complications were assessed using the Clavien-Dindo classification. RESULTS: Median follow-up was 45 months. Median PSA was 5.3 ng/ml. Intraoperative blood loss was 600 ml at a median operating time of 180 min. Surgery in kidney Tx patients was technically feasible. Major complications occurred in 3 patients (ureteral injury, lymphocele and haematoma). Histological evaluation revealed n = 18 ≤pT2 tumours (60.0 %), n = 7 pT3a tumours (23.3 %) and n = 5 ≥pT3b tumours (16.7 %). Continence rate 12 months after surgery, defined as no or one safety pad use, was 73.3 %, while 93.3 % of the patients used ≤2 pads/24 h. After the median follow-up of 45 months, BCR-free survival was 69.0 %. In recurrent men, there was suspicion of metastasis in one patient. No cancer-specific death was observed. Five-year overall survival was 94.4 %. CONCLUSION: The complication rate in patients with solid organ transplantation after RP was low. While histopathological evaluation revealed disease characteristics comparable to non-transplant patients from current RP series, postoperative continence was worse. Immunosuppressive therapy does not seem to lead to an increased rate of tumour progression.
Authors: R Houston Thompson; Bradley C Leibovich; R Jeffrey Karnes; Eric J Bergstralh; Michael L Blute Journal: J Urol Date: 2008-03-04 Impact factor: 7.450
Authors: François M Kleinclauss; Yann Neuzillet; Xavier Tillou; Nicolas Terrier; Guillaume Guichard; Jacques Petit; Eric Lechevallier Journal: Urology Date: 2008-04-24 Impact factor: 2.649
Authors: Rebecca Roth; Sebastian Dieng; Alisa Oesterle; Günter Feick; Günther Carl; Andreas Hinkel; Thomas Steiner; Björn Theodor Kaftan; Frank Kunath; Boris Hadaschik; Simba-Joshua Oostdam; Rein Jüri Palisaar; Mateusz Koralewski; Burkhard Beyer; Björn Haben; Igor Tsaur; Simone Wesselmann; Christoph Kowalski Journal: World J Urol Date: 2020-02-10 Impact factor: 4.226